Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer’s disease.

Identifying CSF-based biomarkers for the β-amyloidosis that initiates Alzheimer’s disease (AD) could provide inexpensive and dynamic tests to distinguish AD from normal aging and predict future cognitive decline.